Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedDec 21, 2024
DataAggregated Company Financials
Companies33
  • 7D0.1%
  • 3M-3.4%
  • 1Y3.1%
  • YTD0.7%

Over the last 7 days, the Biotech industry has risen 1.5%, driven by gains from Mesoblast of 32%. In the last 12 months, the industry was up 4.3%. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 21 Dec 2024AU$148.5bAU$24.7bAU$3.7b24x40.2x6x
Mon, 18 Nov 2024AU$147.2bAU$23.8bAU$3.5b25.7x41.5x6.2x
Wed, 16 Oct 2024AU$158.7bAU$23.0bAU$3.4b28.7x46.7x6.9x
Fri, 13 Sep 2024AU$157.3bAU$23.0bAU$3.4b29.1x46.1x6.8x
Sun, 11 Aug 2024AU$159.6bAU$22.4bAU$3.3b31.5x48.5x7.1x
Tue, 09 Jul 2024AU$153.8bAU$21.9bAU$3.2b32.3x47.9x7x
Thu, 06 Jun 2024AU$148.9bAU$22.1bAU$3.2b31x46.1x6.7x
Sat, 04 May 2024AU$143.1bAU$22.3bAU$3.3b30.1x43.8x6.4x
Mon, 01 Apr 2024AU$147.5bAU$22.5bAU$3.3b30.3x44.7x6.5x
Wed, 28 Feb 2024AU$145.3bAU$22.4bAU$3.3b36.5x43.7x6.5x
Fri, 26 Jan 2024AU$149.0bAU$20.8bAU$2.8b34.1x53.9x7.2x
Sun, 24 Dec 2023AU$143.3bAU$20.2bAU$2.7b34.3x53.8x7.1x
Tue, 21 Nov 2023AU$131.0bAU$20.9bAU$2.8b31.8x47x6.3x
Thu, 19 Oct 2023AU$122.3bAU$21.6bAU$2.8b29.6x43.2x5.7x
Sat, 16 Sep 2023AU$136.5bAU$21.3bAU$2.8b32.2x48.9x6.4x
Mon, 14 Aug 2023AU$136.3bAU$18.5bAU$2.4b38.3x56.8x7.4x
Wed, 12 Jul 2023AU$136.8bAU$18.0bAU$2.3b36.7x58.7x7.6x
Fri, 09 Jun 2023AU$156.1bAU$18.0bAU$2.3b40.9x67.1x8.7x
Sun, 07 May 2023AU$154.3bAU$17.8bAU$2.3b41.4x67.3x8.7x
Tue, 04 Apr 2023AU$148.2bAU$17.9bAU$2.3b40.1x64.4x8.3x
Thu, 02 Mar 2023AU$149.2bAU$17.7bAU$2.3b40.6x65.5x8.4x
Sat, 28 Jan 2023AU$150.7bAU$15.2bAU$2.4b55.5x63.1x9.9x
Mon, 26 Dec 2022AU$147.5bAU$16.0bAU$2.6b46.2x57.7x9.2x
Wed, 23 Nov 2022AU$152.0bAU$16.3bAU$2.6b43.1x58.5x9.3x
Fri, 21 Oct 2022AU$138.8bAU$17.1bAU$2.8b39.6x50.4x8.1x
Sun, 18 Sep 2022AU$145.8bAU$16.0bAU$2.6b45.8x56.9x9.1x
Tue, 16 Aug 2022AU$149.7bAU$15.2bAU$2.7b41.7x54.9x9.9x
Thu, 14 Jul 2022AU$148.5bAU$15.9bAU$2.9b37.4x51.6x9.3x
Sat, 11 Jun 2022AU$136.7bAU$15.2bAU$2.7b34.6x50x9x
Mon, 09 May 2022AU$135.6bAU$15.1bAU$2.8b35.7x49.1x9x
Wed, 06 Apr 2022AU$136.9bAU$14.2bAU$2.6b40.1x53.2x9.6x
Fri, 04 Mar 2022AU$131.8bAU$14.8bAU$2.7b40.2x49x8.9x
Sun, 30 Jan 2022AU$133.0bAU$14.9bAU$2.8b36.6x46.9x8.9x
Tue, 28 Dec 2021AU$152.1bAU$14.5bAU$2.8b42.6x55.1x10.5x
Price to Earnings Ratio

55.1x


Total Market Cap: AU$152.1bTotal Earnings: AU$2.8bTotal Revenue: AU$14.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Biotech Industry Price to Earnings3Y Average 52.2x202220232024
Current Industry PE
  • Investors are pessimistic on the Australian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.9x which is lower than its 3-year average PE of 52.2x.
  • The 3-year average PS ratio of 7.9x is higher than the industry's current PS ratio of 6.1x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 10% per year over the last three years.
  • Revenues for these companies have grown 19% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Australian Healthcare industry?

AU Market-2.74%
Healthcare-0.83%
Biotech0.11%
Biotech0.11%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MSB MesoblastAU$2.4231.5%
+AU$661.9m
706.7%PS291.4x
OPT OptheaAU$0.699.5%
+AU$73.9m
51.6%PS2019.9x
TLX Telix PharmaceuticalsAU$24.740.9%
+AU$70.3m
160.4%PE168.3x
OCC OrthocellAU$1.248.3%
+AU$22.7m
202.4%PS55.8x
ARX Aroa BiosurgeryAU$0.684.6%
+AU$10.3m
-13.9%PS3.4x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

MSB

AU$2.42

Mesoblast

7D

31.5%

1Y

706.7%

RAD

AU$0.024

Radiopharm Theranostics

7D

-17.2%

1Y

-66.2%

TLX

AU$24.74

Telix Pharmaceuticals

7D

0.9%

1Y

160.4%

CYP

AU$0.20

Cynata Therapeutics

7D

11.1%

1Y

66.7%

IMM

AU$0.34

Immutep

7D

-6.8%

1Y

-1.4%

CSL

AU$276.57

CSL

7D

-0.4%

1Y

-2.0%

ACW

AU$0.025

Actinogen Medical

7D

-10.7%

1Y

13.6%

OCC

AU$1.24

Orthocell

7D

8.3%

1Y

202.4%

PYC

AU$1.45

PYC Therapeutics

7D

-3.3%

1Y

45.0%

IMU

AU$0.038

Imugene

7D

-2.6%

1Y

-63.8%

OPT

AU$0.69

Opthea

7D

9.5%

1Y

51.6%

RAC

AU$1.42

Race Oncology

7D

2.5%

1Y

74.7%

CUV

AU$11.79

Clinuvel Pharmaceuticals

7D

-2.8%

1Y

-26.5%

RGS

AU$0.013

Regeneus

7D

160.0%

1Y

8.3%